Efficacy of Nanoencapsulated Daptomycin in an Experimental Methicillin-Resistant Staphylococcus aureus Bone and Joint Infection Model.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
17 11 2021
Historique:
pubmed: 5 10 2021
medline: 15 12 2021
entrez: 4 10 2021
Statut: ppublish

Résumé

Staphylococcus aureus bone infections remain a therapeutic challenge, leading to long and expensive hospitalizations. Systemic antibiotic treatments are inconsistently effective, due to insufficient penetration into the infectious site. In an osteomyelitis model, the single local administration of nanoparticle-encapsulated daptomycin allows sterilization of the infectious sites after 4 and 14 days of treatment, while daily systemic daptomycin treatment for 4 days was not effective. These results demonstrate the great potential of this local antibiotic treatment.

Identifiants

pubmed: 34606337
doi: 10.1128/AAC.00768-21
pmc: PMC8597761
doi:

Substances chimiques

Anti-Bacterial Agents 0
Daptomycin NWQ5N31VKK

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0076821

Subventions

Organisme : Atlangram Biotech

Références

Antimicrob Agents Chemother. 1998 Nov;42(11):2830-5
pubmed: 9797211
Int J Antimicrob Agents. 2010 Dec;36(6):542-4
pubmed: 20851576
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
Antimicrob Agents Chemother. 2021 Mar 18;65(4):
pubmed: 33526492
Bull Acad Natl Med. 2016 Feb;200(2):291-305
pubmed: 29898325
J Antimicrob Chemother. 2011 Apr;66(4):863-6
pubmed: 21393213
Adv Mater. 2017 Sep;29(35):
pubmed: 28699173
Clin Infect Dis. 2013 Jan;56(1):e1-e25
pubmed: 23223583
Drug Deliv. 2015;22(5):627-37
pubmed: 24471983
Cell Host Microbe. 2019 Jul 10;26(1):61-72
pubmed: 31295426
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Clin Infect Dis. 2011 Feb 1;52(3):285-92
pubmed: 21217178
Pharm Res. 2002 Jun;19(6):875-80
pubmed: 12134960
J Hosp Infect. 2012 Sep;82(1):40-8
pubmed: 22738613
J Bone Joint Surg Am. 1996 Apr;78(4):512-23
pubmed: 8609130
Antimicrob Agents Chemother. 2006 Oct;50(10):3245-9
pubmed: 17005801
J Antimicrob Chemother. 2008 Dec;62(6):1462-3
pubmed: 18824457
J Pharm Biomed Anal. 2016 Jan 25;118:17-26
pubmed: 26512995
Clin Orthop Relat Res. 2002 Nov;(404):7-13
pubmed: 12439231
Lett Appl Microbiol. 2011 Mar;52(3):253-7
pubmed: 21204878
Front Microbiol. 2018 Jul 02;9:1441
pubmed: 30013539
Int J Pharm. 2009 Sep 11;379(2):201-9
pubmed: 19409468

Auteurs

Cedric Jacqueline (C)

Université de Nantes, EA3826, IRS2 Nantes Biotech, Nantes, France.
Atlangram, IRS2 Nantes Biotech, Nantes, France.

Jocelyne Caillon (J)

Université de Nantes, EA3826, IRS2 Nantes Biotech, Nantes, France.
Atlangram, IRS2 Nantes Biotech, Nantes, France.

Olivier Meyer (O)

Carlina Technologies, Angers, France.

Eric Dailly (E)

CHU Nantes, Service de Pharmacologie, Nantes, France.
Université Nantes, MIHAR, IRS2 Nantes Biotech, Nantes, France.

Carl Simonsson (C)

Carlina Technologies, Angers, France.

Vincent Lenaerts (V)

Trochylus Pharma Inc., Mississauga, Ontario, Canada.

Karim Asehnoune (K)

Université de Nantes, EA3826, IRS2 Nantes Biotech, Nantes, France.
CHU Nantes, Pôle Anesthésie-Réanimation, Service d'Anesthésie Réanimation Chirurgicale, Nantes, France.

Amokrane Reghal (A)

Atlangram, IRS2 Nantes Biotech, Nantes, France.

Gilles Potel (G)

Université de Nantes, EA3826, IRS2 Nantes Biotech, Nantes, France.
Atlangram, IRS2 Nantes Biotech, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH